



Anagenesis Biotechnologies announces Professor Gordon Keller, joining the Board of Directors

ILLKIRCH GRAFFENSTADEN, France – September 17th, 2019 – Anagenesis Biotechnologies announced today that “Professor Gordon Keller is joining its Board of Directors. Professor Keller is currently Director of the McEwen Stem Cell Institute at the University Health Network and Senior Scientist at the Princess Margaret Cancer Centre in Toronto. He is a scientific co-founder of the biotechnology company Bluerock Therapeutics and brings to the board expertise in the field of stem cells and regenerative medicine”.

“We are proud to welcome Prof. Keller, a world-renowned scientist in the field of stem cell biology”, said Prof. Olivier Pourquié, President of the SAB, co-founder of Anagenesis Biotechnologies and co-inventor of the P2MC technology.

Prof. Gordon Keller is currently the Director of the McEwen Stem Cell Institute at the University Health Network in Toronto. He is a scientific co-founder of BlueRock Therapeutics and is best known for his research in lineage specific differentiation of mouse and human pluripotent stem cells. His lab was one of the first to successfully differentiate human pluripotent stem cells into the multiple cardiac lineages found in the human heart.

Prof. Gordon Keller received a PhD in Immunology from the University of Alberta in 1979. Following a post-doctoral fellowship at the Ontario Cancer Institute in Toronto, he moved to Europe and worked as a member of the Basel Institute for Immunology in Switzerland and then as a visiting professor at the Research Institute of Molecular Pathology in Austria. Prof. Keller relocated to the United States in 1990 to a faculty position at the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado. In 1999 he moved to New York, to work in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine. In 2005, he was appointed as the inaugural Director of the Black Family Stem Cell Institute at Mt. Sinai. Prof. Keller returned to Canada in 2007 to take on the role of Director of the McEwen Stem Cell Institute.

“I am excited to work with Olivier, Jean-Yves and the excellent scientists at Anagenesis Biotechnologies to develop new approaches to enhance muscle regeneration” said Prof. Gordon Keller

“We are enthusiastic to welcome Prof. Gordon Keller said Jean-Yves Bonnefoy, PhD, President and Chief Executive Officer of Anagenesis Biotechnologies. His knowledge and experience in the field of stem cells will be an asset for Anagenesis Biotechnologies development in the coming years.”

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing new treatments against muscle diseases (genetic such as Duchenne Muscular Dystrophy (DMD) and chronic such as sarcopenia and cachexia). The company was cofounded by Prof. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is a Professor at Harvard Medical School and the Brigham and Women’s Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. For more information, please visit www.anagenesis-biotech.com.

Anagenesis Biotechnologies’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle, brown fat, dermis, endothelial cells, cartilage and bone. The P2MC technology was developed with the support of AFM-telethon, INSERM, CNRS and Université de Strasbourg.

MEDIA CONTACT:

Jean-Yves Bonnefoy

President & CEO

+33 620 885 092

jybonnefoy@anagenesis-biotech.com